65,437 trials
Bipolar Mania · Bipolar Disorder
Primary: Time to Intervention for a Mood Episode During Double Blind Period — 172.159; 143.133 Days — p=0.0104
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Diabetes Mellitus
Primary: Number of AST Results Within +/- 15mg/dL or +/- 20% of Fingerstick (FS)Blood Glucose Results — 96; 93 number of AST Blood Glucose Results
Meningitis · Meningococcal Infection
Primary: Participants With Serum Bactericidal Activity of ≥ 1:8 for Each Menactra® Vaccine Serogroups Pre-vaccination and 28 Days Post-booster or Post-primary Dose Vaccination…
Neoplasms, Breast
Primary: Overall Tumor Response — 1; 8; 18; 29 participants
Seasonal Allergic Rhinitis
Primary: Number of Patients With Clinical Adverse Experiences (CAEs) — 73; 35; 207; 98 Participants
Dyslipidemia
Primary: Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid — 116; 121 μg·hr/mL
Embolism, Pulmonary
Primary: The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE) — 0; 0 percentage of participants
Osteoarthritis, Knee
Primary: Observed Pain Scores on 50-foot Walk Test During the Double-blind Study — 55.6; 54.7; 30.0; 36.1 units on a scale
Carcinoma, Renal Cell
Primary: Progression-Free Survival (PFS), Core Radiology Assessment — 48.3; 22.1 weeks — p=<0.0001
Ametropia
Primary: Best Corrected Visual Acuity — 0.65; 1.33; 98.06; 98.67 Percentage of Participants
Hypokalemia
Primary: Plasma Potassium — 4.0; 4.0; 4.1; 3.7 mmol/l — p=0.007
Non Small Cell Lung Cancer
Primary: Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) — 28.6 percentage of participants
Schizoaffective Disorder · Psychotic Disorder
Primary: Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score at Baseline. — 91.7; 92.3 points on a scale — p=0.774
Colorectal Neoplasms · Neoplasms
Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 9; 5; 12 participants